SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is trending after closing a $40 million private placement, which has ignited a rapid surge in its share price. The community is actively debating the implications of the placement's per-share cost versus current trading levels, with many traders anticipating further momentum and a potential short squeeze.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is surging amid escalating tensions in the Middle East and the effective closure of the Strait of Hormuz, driving community debate on whether oil's parabolic rise is sustainable against potential strategic reserve releases by the G7.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following strong 12-month Phase 2 data for its bladder cancer candidate NDV-01 and significant new financing to advance its clinical pipeline. The community is actively discussing the promising trial results and the implications of the capital raise, with some monitoring for potential dilution.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Calamp Corp. is currently trending due to its Chapter 11 bankruptcy filing and plan to go private, which is expected to eliminate existing shareholder equity. Investors are actively discussing the impending delisting and the ultimate value of their holdings.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

AGH is trending due to its announced merger with drone manufacturer Powerus, a company backed by Eric Trump and Donald Trump Jr., which is transforming it from a golf course operator into a public defense-drone entity. This significant pivot is driving massive community discussion and high volume, fueled by anticipation of government contracts amid increasing demand for U.S.-made drone technology.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. trends amid the upcoming CEO transition to Josh D'Amaro on March 18 and the successful debut of Pixar's 'Hoppers,' fueling community discussion over whether these catalysts, alongside a new stock buyback, can address ongoing concerns about content performance and valuation.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is surging on heightened speculation surrounding a potential acquisition, particularly an eBay deal, alongside community excitement following recent social media activity from "Roaring Kitty" and anticipation for its upcoming Q4 earnings report, fueling widespread chatter about a significant breakout.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is surging as its new agreement with Novo Nordisk to sell branded Ozempic and Wegovy, coupled with the dismissal of a patent lawsuit, fundamentally transforms its market position in the booming GLP-1 sector. The community is actively debating a massive short squeeze and long-term upside, with many seeing the move as eliminating the main bear thesis and validating Hims' growth strategy.

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Solid Biosciences is trending following an oversubscribed $240 million private placement bolstering its cash runway and recent positive regulatory updates across its Duchenne, Friedreich's Ataxia, and cardiac gene therapy programs, igniting strong institutional interest and short-squeeze speculation among the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Firefly Neuroscience Stock On Friday?

Firefly Neuroscience stock climbs after a major expansion in brain scan partnerships and rapid growth in its EEG data network.read more...

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion PR Newswire NEW YORK, March 5, 2026 GAD...

Promising Small Cap Stocks To Follow Today - March 4th

Rapt Therapeutics, Actelis Networks, and Firefly Neuroscience are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly...

Firefly Neuroscience Skyrockets Brain Scan Breakthrough Fuels Rally

Firefly Neuroscience stock surges after rapid growth in brain scans, partnerships, and progress toward a human brain AI foundation model.read more...

<ul class="summary-bullets"><li>The company now partners with 99 commercial sites as of the end of 2025, a 1,880% year-on-year surge.</li><li>Similarly, Firefly has completed over 10,800 EEG/ERP brain scans in 2025, a 3,227% YoY increase.&nbsp;</li><li>The company uses NVIDIA L40S GPU accelerators to power EEG/ERP processing.&nbsp;</li></ul>Firefly Neuroscience, Inc. (AIFF) on Wednesday reported a notable surge in its operations, including an expansion of its commercial presence and brain scan activity.&nbsp;The company emphasized that the surge in data, combined with advanced supercomputing resources, can accelerate AI-driven biomarker discovery.<h2 class="st-heading-2">Expansion and Data Growth</h2>Firefly said it has achieved more than a 20-fold increase in its commercial footprint and a 33-fold jump in EEG/ERP brain scan volumes over the past year.The company now partners with 99 commercial sites, collectively completing over 10,800 EEG/ERP brain scans by the end of 2025, a breakout surge of 1,880% and 3,227% respectively, from 2024 figures.<blockquote>“With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”-Greg Lipschitz, CEO, Firefly&nbsp;</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/AIFF">Firefly Neuroscience stock</a> traded over 45% in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">AI-Powered Brain Analysis</h2>Firefly uses artificial intelligence to better understand how the brain works. It builds tools that help doctors and researchers study brain activity more clearly and help in diagnosing and tracking conditions such as depression, dementia, anxiety, concussions, and ADHD.The company has created a large collection of brain scan data, with more than 191,000 EEG and ERP scans.AIFF stock has declined by more than 72% over the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/googl-meta-openai-president-trump-meet-big-tech-leaders-launch-ratepayer-protection-pledge/cZd9mKHRI58">GOOGL, META, OPENAI: President Trump Will Reportedly Meet Big Tech Leaders To Launch Ratepayer Protection Pledge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

AIFF Stock Soars 45% Pre-Market Today — What’s Fueling The Rally? 

AIFF company said it has achieved more than a 20-fold increase in its commercial footprint and a 33-fold jump in EEG/ERP brain scan volumes over the past year.

Equity

The company said it has achieved more than a 20-fold increase in its commercial footprint and a 33-fold jump in EEG/ERP brain scan volumes over the past year.


SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

Firefly Neuroscience rallied in its strongest session in more than a month on Tuesday after unveiling its new Clear Platform, a proprietary electroencephalogram (EEG) preprocessing technology built with Nvidia’s L40S GPU acceleration.The stock closed up 4.6% at $2.71 on Tuesday and added another 1.5% in after-hours trade.The medtech firm stated that the system achieves substantial processing speed gains of 60–80% while maintaining high signal quality, thereby enabling cleaner brainwave data for biomarker discovery and clinical research.&nbsp;Firefly stated that the platform could unlock new AI-driven insights to advance the diagnosis, treatment, and monitoring of neurological and psychiatric conditions.“Data quality is the foundation of clinical insight,” said Gil Issachar, Firefly’s Chief Technology Officer. “By combining our advanced preprocessing methods with Nvidia GPU acceleration, the Clear Platform represents the achievement of a key milestone along our path of building a foundation model of the human brain.”The launch comes months after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aiff-stock-soars-after-nvidia-connect-program-nod/ch5au23RuF">Firefly was accepted into the Nvidia Connect Program</a>, which provides participating companies with software development resources and technical training.CEO Greg Lipschitz said the rollout will play a central role in the company’s growth strategy, supporting efforts to discover and advance breakthrough brain biomarkers that can aid pharmaceutical R&amp;D, clinical trials, and patient care.Firefly develops AI-driven brain health tools and already holds FDA clearance for its Brain Network Analytics technology, which supports diagnosis and treatment monitoring for depression, dementia, anxiety, concussions, and ADHD.On Stocktwits, retail sentiment for Firefly was ‘extremely bullish’ amid an 11,700% surge in 24-hour message volume.One user described the stock as “a pound on the table” buy, calling it a potential multibagger in its early stages.<stembedurl>https://stocktwits.com/elgreg_2002/message/626646720</stembedurl>Another user predicted Firefly’s software could become the future of EEG diagnostics, noting that current brainwave readings are often noisy and time-consuming to interpret.&nbsp;With AI-driven clarity, they said, the company could cut delays in diagnosis and “be making a fortune.”<stembedurl>https://stocktwits.com/megamaven/message/626633235</stembedurl><a href="https://stocktwits.com/symbol/AIFF">Firefly Neuroscience’s stock</a> has risen 2.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Firefly Neuroscience’s stock has risen 2.3% so far in 2025. (Photo credit: Getty Images)

Firefly Neuroscience Stock Scores Biggest Gain In Weeks On Nvidia Brain Platform Boost: Retail Says ‘Pound On The Table’ Buy

The surge followed the debut of Firefly’s Clear EEG technology, which promises faster, cleaner brain data for biomarker discovery. 

This Hidden-Gem Stock Is Skyrocketing on Nvidia News. Should You Buy It Now?

Firefly Neuroscience’s stock has skyrocketed over 200% in five days after joining Nvidia’s Partner Connect Program.

Shares of Firefly Neuroscience Inc. surged more than 30% on Wednesday afternoon, reaching their highest levels in over nine months.&nbsp;The micro-cap medtech firm’s stock was experiencing the largest jump in retail following among health care stocks on Stocktwits, with trading volume nearly 10 times the daily average of 7.29 million shares.The rally followed Firefly’s announcement on Tuesday that it had been accepted into the Nvidia Connect program, which provides participating companies with software development resources and technical training.Firefly plans to leverage these tools to build a human brain foundation model using its FDA-cleared Brain Network Analytics (BNA) technology platform.&nbsp;Developed with artificial intelligence and machine learning, BNA aims to enhance doctors’ insights into brain function and improve diagnostic accuracy for patients with neurological and mental disorders.That announcement sent Firefly shares rocketing 170% higher on Tuesday, marking their best session ever.On Stocktwits, Firefly — currently valued at just $88.6 million — has drawn increasing attention.&nbsp;Its retail following has soared by nearly 70% over the past month, while message volume has exploded by more than 168,000%.&nbsp;A poll on the platform asking whether the stock’s squeeze had real momentum saw 62% of respondents voting “Yes, $20+ soon,” while 28% called it a “pump and dump.”<figure class="image"><img style="aspect-ratio:1290/644;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AIFF_Stocktwits_Poll_On_Feb_12_0cf377b1b2.png" alt="AIFF Stocktwits Poll On Feb 12.png" width="1290" height="644"><figcaption>AIFF Stocktwits Poll On Feb 12</figcaption></figure>Short interest in Firefly has jumped from 2.6% at the start of the year to 26.7% by the end of January, according to Koyfin data.&nbsp;The company went public via a $45 million reverse merger with IT group WaveDancer last August, and shares have gained nearly 37% since then.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, Firefly — currently valued at just $88.6 million — has drawn increasing attention. | Image source: Getty Images

Firefly Neuroscience Leads Health Care Retail Follower Surge After Nvidia Connect Program Nod Sends Stock Soaring

The medtech firm plans to leverage these tools to build a human brain foundation model using its FDA-cleared Brain Network Analytics technology platform.

Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. It offers Brain Network Analytics (BNA) platform, a software as a medical solution for the diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. The company was founded in 1979 and is headquartered in Kenmore, NY.

AIFF
Firefly Neuroscience Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AIFF News

AIFFFirefly Neuroscience Inc.